Menu Search
Equities

Novo Nordisk A/S

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NOVA:STU

Novo Nordisk A/S

Actions
  • Price (EUR)40.15
  • Today's Change3.40 / 9.25%
  • Shares traded14.32k
  • 1 Year change-52.43%
  • Beta0.7377
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in USD (TTM)48.75bn
  • Net income in USD16.16bn
  • Incorporated1931
  • Employees68.79k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVO B:CPH since
announced		Transaction
value
Metsera IncDeal withdrawn30 Oct 202530 Oct 2025Deal withdrawn-11.75%9.68bn
Akero Therapeutics IncDeal completed09 Oct 202509 Oct 2025Deal completed-23.13%5.11bn
Data delayed at least 15 minutes, as of Feb 06 2026 15:59 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.